About Casebia

Scaled for Success

Pioneering a new field of medicine requires more than vision. It takes a long-term commitment, sufficient resources and a collaborative approach to seize on the emerging breakthroughs that will define the future.

Casebia Therapeutics, a 50-50 joint venture between CRISPR Therapeutics and Bayer, was created to accelerate the field of gene editing therapeutics today, and for the long haul. Drawing on CRISPR/Cas9 technology and expertise from CRISPR Therapeutics and the distinctive disease know-how and protein engineering capabilities of Bayer, we are working to redefine what’s possible for patients with a wide range of inherited diseases.

Read more read more




Axel Bouchon, Ph.D. (chair)
Head of Bayer Lifescience Center
Bayer AG
Jim Burns, Ph.D.
President and CEO
Casebia Therapeutics
Jürgen Eckhardt, M.D.
Head of Bayer Venture Investments
Samarth Kulkarni, Ph.D.
Chief Executive Officer
CRISPR Therapeutics
Tony Ho, M.D.
Head of Research and Development
CRISPR Therapeutics
Jörg Möller, M.D.
Head of Research and Development, Pharmaceutical Division
Bayer AG
Rodger Novak, M.D.
Chairman of the Board, Founder and President CRISPR Therapeutics